VolitionRx

company

About

VolitionRx develops easy to use blood-based cancer tests to accurately diagnose a range of cancers.

  • 51 - 100

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$1.50M
Industries
Biotechnology,Health Care,Health Diagnostics
Founded date
Jan 1, 2010
Number Of Employee
51 - 100
Operating Status
Active

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid which is an indication that disease is present.

As cancer screening programs become more and more widespread, its products aim to help to diagnose a range of cancers quickly, simply, accurately, and cost-effectively. Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and worldwide.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$1.50M
VolitionRx has raised a total of $1.50M in funding over 2 rounds. Their latest funding was raised on Aug 3, 2022 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 3, 2022 Post-IPO Debt $1.50M 1 Namur Invest Detail

Investors

Number of Lead Investors
Number of Investors
1
1
VolitionRx is funded by 1 investors. Namur Invest are the most recent investors.
Investor Name Lead Investor Funding Round
Namur Invest Yes Post-IPO Debt